In our network pharmacology study on diabetes, we analyzed plant compounds, identified top hub genes, and selected five intersecting genes based on degree, betweenness, and closeness algorithms. We now aim to perform molecular docking for the top five hub genes. If these genes are primarily linked to cancer, should we use a cancer-related protein or a diabetes-related protein for docking?